| SScPAH+ N = 11 | SScPAH- N = 13 | Control N = 10 |
---|---|---|---|
Age, yr | 70.1 ± 9.6 | 66.2 ± 11.2 | 59.7 ± 6.5 |
Height, m | 1.6 ± 0.1 | 1.7 ± 0.1 | 1.7 ± 0.1 |
Male/Female | 0/9 | 0/12 | 2/8 |
Limited cutaneous SSc (%) | 100 | 100 | Â |
Haemoglobin, mmol/l | 7.8 ± 1.2†| 8.0 ± 0.6‡ | 8.6 ± 0.8 |
Raynaud's phenomenon (%) | 100 | 92 | Â |
Raynaud's phenomenon at PFT, years | 19.2 ± 10.6* | 6.6 ± 8.3 |  |
Autoantibodies (no.) | Â | 12 | Â |
ANA | 10 | 6 | Â |
Anti-centromere | 7 | 5 | Â |
Anti-topoisomerase | 0 | Â | Â |
Modified Rodnan skin score | 14.1 ± 5.7 | 11.9 ± 5.9 |  |
Smoking status | 7/3/1 | 6/4/2 | 8/2/0 |
Never/former/current (no.) | Â | Â | Â |
6-minute walking distance, m | 326 ± 102 | 430 ± 127 |  |
SvO2, % | 62.7 ± 6.6* | 72.5 ± 2.0 |  |
HRCT fibrosis score‡ | 4.9 ± 3.4†| 4.1 ± 3.4 |  |
HRCT ground glass score‡ | 7.1 ± 5.8†| 3.1 ± 5.5 |  |
HRCT total fibrosis score‡ | 12.1 ± 6.8†| 7.4 ± 8.5 |  |